ABB-N 0 ROK-N 5.41 SIEGY-OTC 0 NVDA-Q 3.82 BAC-N 0.43 MSCI-N -5.07 GRBK-Q 0.23
Daily Stock Opinions and Ratings
The ultimate 360° Tracker Your financial life in one place, automatically
Stockchase Opinions

Ed Ho Axcan Pharmaceuticals AXP-T STRONG BUY Dec 11, 2000

Products selling very well. Sales force based in US
Ed HoEd Ho
Unknown
Unlock Rating
$14.950

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Axcan Pharmaceuticals(AXP-T)

Jan 31, 2002
Had a nice run. May be a bit high now.
Malvin SpoonerMalvin Spooner
Unknown
Unlock Rating
$21.500

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Axcan Pharmaceuticals(AXP-T)

Jan 20, 2003
A good long term hold. They focus on their earnings. Well managed.
Pierre BernardPierre Bernard
Unknown
Unlock Rating
$17.850

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Axcan Pharmaceuticals(AXP-T)

May 20, 2003
Its OK earnings wise. They are trying to make a hostile take over which looks expensive. Core business is OK.
Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
Unknown
Unlock Rating
$16.930

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Axcan Pharmaceuticals(AXP-T)

Nov 03, 2003
The entire US financial sector is attractive. Their brokerage sector is growing rapidly. Expects travel business will pick up.
John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$47.230

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Axcan Pharmaceuticals(AXP-T)

Nov 11, 2003
Has a very good ROE. Efficient balance sheet structure. Continuing to grow their earnings. Valuation is reasonable.
Peter Arender, CFAPeter Arender, CFA
Unknown
Unlock Rating
$17.400

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Axcan Pharmaceuticals(AXP-T)

Nov 09, 2004
Last news was that R&D spending would be higher than the street anticipated. Launching a product that could be a $200 million product.
Danny TomkaDanny Tomka
Owned
Unlock Rating
$19.500

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Axcan Pharmaceuticals(AXP-T)

Nov 24, 2004
A very focused (gastro intestinal) pharmaceutical company and as a result, it is very profitable. You pretty well get a free call option on a potentially block-buster drug called Itax. Huge market in North America.
Fred PynnFred Pynn
Owned
Unlock Rating
$20.980

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Axcan Pharmaceuticals(AXP-T)

Apr 14, 2005
Part pharmaceutical and part drug development. Very profitable. Strong balance sheet and lots of cash flow. Generates about US$1.50 free cash flow every year. In a very stable gastro-intestinal market. They're also in-licence some drugs which gives them some pretty good upside. Trading at about US$14 with $1 a share free cash on the balance sheet.
Chris FernycChris Fernyc
Owned
Unlock Rating
$18.600

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

ANET-N 2.09$70.76
GS-N 9.32$529.31
PAYC-N 7.71$219.23
VRT-N 6.18$78
GEV-N 10.02$336.09

Today's Top Picks

ABB-N 0$50.68
ROK-N 5.41$239.83
SIEGY-… 0$109.48
NVDA-Q 3.82$102.71
BAC-N 0.43$38.75

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

CAT-N 4.6$295.77
BCE-T 0.07$30.84
KHC-Q -0.11$30.09
ECN-T 0.09$2.84
DHI-N -0.17$124.79

Most Recent Experts

Kim Bolton

Black Swan Dexteritas

Jim Cramer - Mad Money

CNBC

Paul Harris, CFA

Harris Douglas Asset Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

© Stockchase Inc.